Geoffrey R Oxnard

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
  2. ncbi When progressive disease does not mean treatment failure: reconsidering the criteria for progression
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1234, Boston, MA 02215
    J Natl Cancer Inst 104:1534-41. 2012
  3. ncbi Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA
    Arch Pathol Lab Med 136:1205-9. 2012
  4. ncbi Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
  5. ncbi Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
  6. ncbi Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
  7. ncbi New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 17:5530-7. 2011
  8. ncbi Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
  9. ncbi Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
  10. ncbi Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 78:161-6. 2012

Detail Information

Publications15

  1. ncbi Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
    ..Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies...
  2. ncbi When progressive disease does not mean treatment failure: reconsidering the criteria for progression
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1234, Boston, MA 02215
    J Natl Cancer Inst 104:1534-41. 2012
    ....
  3. ncbi Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA
    Arch Pathol Lab Med 136:1205-9. 2012
    ....
  4. ncbi Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
    ..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI...
  5. ncbi Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
    ..To examine this observation and define the course of patients following TKI discontinuation, we systematically evaluated patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib...
  6. ncbi Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
    ..We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations...
  7. ncbi New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 17:5530-7. 2011
    ..In this review, we discuss recent advances in the understanding of acquired TKI resistance in EGFR-mutant lung cancer and review therapeutic progress with second generation TKIs and combinations of targeted therapies...
  8. ncbi Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  9. ncbi Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
    ..In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI...
  10. ncbi Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 78:161-6. 2012
    ..Compare the clinical characteristics, rate of recurrent venous thromboembolism (VTE) and outcome of suspected and unsuspected pulmonary embolism (PE) detected on computed tomography in patients with lung cancer...
  11. ncbi Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
    Geoffrey R Oxnard
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 24:392-9. 2010
    ..Currently active trials are referenced using their ClinicalTrials.gov identifier...
  12. ncbi Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor Genotypes
    Geoffrey R Oxnard
    Authors Affiliations Lowe Center for Thoracic Oncology Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts
    Clin Cancer Res 19:1634-6. 2013
    ..Clin Cancer Res; 19(7); 1634-6. ©2013 AACR...
  13. ncbi New targetable oncogenes in non-small-cell lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 31:1097-104. 2013
    ....
  14. ncbi Non-small cell lung cancer in octogenarians: treatment practices and preferences
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Thorac Oncol 2:1029-35. 2007
    ..Treatment practices in this patient population are poorly described. In this report, we describe the treatment of a population of very elderly patients with NSCLC at a large teaching hospital...
  15. ncbi Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, USA
    Lung Cancer 52:141-8. 2006
    ..Application of the RECIST response criteria to mesothelioma thickness measurements yields PR and PD classifications based on smaller volume changes than for spherical tumors...